Bio-Techne Corp (NASDAQ:TECH) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• Analyst consensus: Bio‑Techne has a consensus recommendation of "Moderate Buy" from 14 analysts (9 buy, 1 strong buy, 3 hold, 1 sell) with an average 1‑year price target of $72.77.
• Quarterly results: The company beat estimates (EPS $0.46 vs. $0.43; revenue $295.9M vs. $290.2M) despite revenue declining 0.4% year‑over‑year, and shares trade around $57.53 with a market cap of about $9B and a P/E of ~113.
• Ownership and payout: Institutional investors own roughly 98.95% of the stock with several firms materially increasing stakes, and Bio‑Techne pays a modest annual dividend of $0.32 (yield ~0.6%, payout ratio ~62.8%).

Bio-Techne Corp (NASDAQ:TECH - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the fourteen ratings firms that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation, nine have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $72.7692.

A number of research analysts have issued reports on TECH shares. TD Cowen restated a "buy" rating on shares of Bio-Techne in a research note on Tuesday, March 17th. Zacks Research upgraded Bio-Techne from a "strong sell" rating to a "hold" rating in a research note on Monday, February 9th. Benchmark restated a "buy" rating on shares of Bio-Techne in a research note on Tuesday, February 3rd. UBS Group restated a "buy" rating and issued a $79.00 price objective (up from $70.00) on shares of Bio-Techne in a research note on Thursday, February 5th. Finally, Stifel Nicolaus set a $65.00 price objective on Bio-Techne and gave the company a "hold" rating in a research note on Thursday, February 5th.

Bio-Techne Trading Up 3.6%

NASDAQ TECH opened at $57.53 on Tuesday. The firm has a market capitalization of $9.00 billion, a P/E ratio of 112.81, a PEG ratio of 3.65 and a beta of 1.49. The business has a fifty day simple moving average of $56.32 and a 200 day simple moving average of $59.94. Bio-Techne has a 12 month low of $46.01 and a 12 month high of $72.16. The company has a current ratio of 4.54, a quick ratio of 3.08 and a debt-to-equity ratio of 0.13.

Bio-Techne (NASDAQ:TECH - Get Free Report) last released its quarterly earnings results on Wednesday, February 4th. The biotechnology company reported $0.46 EPS for the quarter, beating analysts' consensus estimates of $0.43 by $0.03. The business had revenue of $295.88 million during the quarter, compared to analyst estimates of $290.20 million. Bio-Techne had a return on equity of 13.94% and a net margin of 6.67%.Bio-Techne's quarterly revenue was down .4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.42 EPS. On average, analysts predict that Bio-Techne will post 1.67 EPS for the current fiscal year.

Bio-Techne Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, February 27th. Shareholders of record on Monday, February 16th were paid a $0.08 dividend. This represents a $0.32 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date was Friday, February 13th. Bio-Techne's dividend payout ratio is 62.75%.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of TECH. Morgan Stanley grew its stake in shares of Bio-Techne by 15.3% during the 4th quarter. Morgan Stanley now owns 8,345,414 shares of the biotechnology company's stock worth $490,794,000 after acquiring an additional 1,107,536 shares during the period. State Street Corp grew its stake in shares of Bio-Techne by 1.0% during the 4th quarter. State Street Corp now owns 5,812,032 shares of the biotechnology company's stock worth $341,806,000 after acquiring an additional 58,639 shares during the period. Wellington Management Group LLP grew its stake in shares of Bio-Techne by 12.1% during the 4th quarter. Wellington Management Group LLP now owns 5,734,049 shares of the biotechnology company's stock worth $337,219,000 after acquiring an additional 618,916 shares during the period. Price T Rowe Associates Inc. MD grew its stake in shares of Bio-Techne by 21.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,075,194 shares of the biotechnology company's stock worth $239,663,000 after acquiring an additional 725,050 shares during the period. Finally, Massachusetts Financial Services Co. MA grew its stake in shares of Bio-Techne by 164.4% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,012,818 shares of the biotechnology company's stock worth $235,994,000 after acquiring an additional 2,495,328 shares during the period. Institutional investors own 98.95% of the company's stock.

Bio-Techne Company Profile

Bio-Techne Corporation NASDAQ: TECH is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.